Ind-Swift Laboratories Limited has released an investor presentation detailing its significant strategic transformation, including the ₹1,650 crore divestment of its API & CRAMS business to Synthimed Labs Pvt. Ltd. This move has resulted in the company becoming net debt-free. The merger of Ind-Swift Limited into ISLL, effective March 31, 2024, has consolidated operations into a unified, pure-play formulations platform with a reported revenue base of ₹550 crore, primarily driven by exports.

The company is focusing on accelerating growth through a FY27 accretive Viatris partnership to strengthen its CDMO visibility and expanding its own-brand footprint in UAE and Central Asia, where it has over 400 registered products. Ind-Swift Laboratories is targeting to double its revenue by FY29, supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM), and CMO (42% GM), aiming for sustained profitability.

The presentation also outlines the company's evolution, its manufacturing infrastructure across domestic and global business units, and its R&D capabilities. Key financial highlights for Q2 FY26 show total income of ₹170.50 crore and EBITDA of ₹19.34 crore, with a 6.34% increase year-on-year. The company's strategic initiatives include leveraging global demand surges, accelerating export growth, creating high-value IP, and expanding in high-margin therapies, all while benefiting from favorable regulatory and policy environments.